Legal Cannabis Expected to Benefit From New Technologies

NEW YORK, October 12, 2017 /PRNewswire/ --

According to a report by New Frontier Data, medical cannabis sales in 2017 are forecast to grow to $5.3 billion, which is 67% of total cannabis sales. The report projects that by 2025, medical sales in current legal states are forecast to grow to $13.2 billion, which will account for 55% of total cannabis sales. Adult use sales in 2017 are forecast to reach $2.6 billion, or rising to $10.9 billion by 2025. New Frontier also indicates that legal cannabis sales in California alone are projected to reach $2.8 billion in 2017 and $6.6 billion by 2025, with a compound annual growth rate of 12% over the next eight years. Glance Technologies Inc (OTC: GLNNF), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), INSYS Therapeutics, Inc. (NASDAQ: INSY), Cannabis Sativa, Inc. (OTC: CBDS)

One major obstacle of the legal cannabis market is to raise money. Because of discrepancy between states and federal laws banks still often refuse to open checking accounts and do not lend money for cannabis business. Yet, despite the discrepancies, the situation improves over time, in large thanks to technology and electronic payment systems. A report by paymentssource.com indicates that a shop that handles its payments electronically is less able to commit tax fraud and less likely to be a target of theft. As result, some concerns that financial institutions have may be dealt with. "You're starting to see a tendency, a healthy capitalistic tendency, for banks and credit unions that know they are missing out on or losing money by not working with marijuana businesses," said Serge Chistov, an investor and financial consultant for Honest Marijuana, a recreational grow house in Denver, Colorado.

Glance Technologies Inc (OTCQB: GLNNF) also listed on the Canadian Stock Exchange under the Ticker 'GET'. Just earlier today the company announced breaking news that, "Cannapay Financial, a significant subsidiary of Glance, has acquired an Ayurvedic wellness product line. Cannapay will develop new products and a supporting lifestyle app to distribute content that will enable customers to realize the beneficial properties of Cannabis and THC."

Ayurvedic medicine treats Cannabis as an ancient holistic plant. This acquisition is the second acquisition of Ayurvedic products Cannapay has made this quarter. Cannapay intends to partner with licensed producers to create cannabis infused products to sell in Canada and distribute internationally where legal to do so.

"We are working to develop a meaningful, insights-driven brand and the supporting content with the underlying goal of educating cannabis consumers about how to most effectively utilize these products to achieve their health and wellness goals. Just as the practice of Ayurveda is based on the science of life, we are building a brand centered on the science of people," says Penny Green, Glance Technologies President. Products will include items such as: soap bars, massage oils, candles, bubble bath, bath bombs, body sprays, moisturizer, bath salts and more. These will be created with essential oils and herbs, salts, hemp and other ingredients and will be used for skin rejuvenation, relaxation and overall rejuvenation, pain relief, stress reduction, skin repair, deep cleaning and more.

The lifestyle app will focus on wellness practice, guide users through exercises and meditations, as well as help them to understand what various wellness products do and which ones are right for them. Cannapay has acquired the products, formulas relating to the development and composition of the aforementioned products, the results of all market and product research and all other intellectual property related to the products as well as the right to reformulate the products to include THC.

Cannapay has also appointed Bhavna Solecki as its Director of Products and Digital Content. Ms. Solecki is an Ayurvedic Holistic Practitioner and is the sole founder of Inner Evolution Healing Center Ltd. She is a recognized speaker and workshop facilitator for health and wellness events. She has been involved in research and development for pain and stress management for acute and chronic illnesses for the past fifteen years working with plant medicine and ancient therapies. Cannapay is investing significant resources into developing trusted brands that can be distributed internationally, marketed and sold through its mobile payment cannabis lifestyle app.

"We are now engaging industry leaders in branding, product development, digital educational content production, regulatory experts and application user experience artists to create brands that will have tremendous impact on the international Cannabis community, and translating to significant revenues for Cannapay," says Green.

Cara Therapeutics Inc. (NASDAQ: CARA) is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic pain, a condition currently without consistently effective therapies. Studies on the effects of cannabis (marijuana) have led to the recent discovery of an endogenous system of ligands in humans involved in a number of physiological processes including pain and inflammation.

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is dedicated to improving the lives of people with severe health conditions where there is a high unmet medical need by developing and commercializing pharmaceutically-produced transdermal cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. On September 28, 2017, the company announced positive top line results from an open label exploratory Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). The study successfully met its primary endpoint, achieving a 46% improvement (p<0.0001) in the total score of Anxiety, Depression, and Mood Scale (ADAMS) at week twelve compared to baseline.

INSYS Therapeutics, Inc. (NASDAQ: INSY) is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients' quality of life. Recently, the company announced that it has extended the compassionate use studies of its proprietary oral formulation of cannabidiol (CBD) for the treatment of refractory pediatric epilepsy, enabling patients from previous clinical trials of the investigational medicine to continue receiving it according to the protocols originally accepted by the U.S. Food and Drug Administration (FDA) and under the supervision of their physicians.

Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. On September 6, 2017, the company announced that it has granted an exclusive license to the Sowilde Management Group, Inc. to allow Sowilde to produce products under the Company's 'hi' and 'White Rabbit' brands. The first products offered to the market by Sowilde are the White Rabbit line of cannabis sprays and cannabis mints and hi Infused Wild Honey. White Rabbit offers fast acting low dose cannabis oral sprays and low dose cannabis mints. Both the spray and the mints are formulated as CBD, THC and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1 and 20:1 variations of each. hi Honey, is a rich, dark, Wild Raw Honey from African mountain bee that is infused with THC or CBD and sourced from a company that supports a native bee population as well as creates sustainable livelihoods for two indigenous groups.  

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz  

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com expects to be compensated five thousand dollars for financial news dissemination and pr services by glance technologies inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news dissemination and pr advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com.

For further information:
[email protected]
+1-877-601-1879

Url: www.FinancialBuzz.com

SOURCE FinancialBuzz.com